Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

ABSTRACT

Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.

This application claims priority to U.S. provisional application Ser.No. 60/182,685, filed on Feb. 15, 2000 that, while pending at the timethe instant non-provisional was filed, is now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention concerns vaccines effective for treating cancer.This invention particularly concerns a universal cancer vaccineinvolving telomerase reverse transcriptase as a specific tumor antigen,a method for its use for targeting cytotoxic T lymphocytes to tumorcells, and a method for induction and/or augmentation of a cancerpatient's immune response against his tumor.

2. Description of the Prior Art

Various publications are referenced within this application. Thedisclosures within these publications are hereby incorporated byreference, in their entireties, into this application so that the stateof art to which this invention pertains is more fully described.

The prevalent cancer treatments of choice heretofore are surgery,radiation, chemotherapy or a combination thereof. With the exception ofa very few cancers, prognosis has not been very satisfactory, resultingin death of the patient after sometimes horrendous suffering from thetreatments themselves.

Many medical research laboratories throughout the world are doingresearch directed towards developing effective, non-invasive treatmentsfor arresting the growth and destroying both benign and malignanttumors. However, treatments employed, both in clinical trials or generalpractice, have not demonstrated appreciable levels of tumor cellnecrosis thus far.

Aspecific Methods of Treatment

One method for treating tumors, brachytherapy, involves injectingmicroscopic clumps of the protein albumin directly into the tumor. Asuitable amount of radioactive phosphorous is then added through thesame needle. The albumin clogs capillaries within the tumor, thereby,preventing the release of radioactive phosphorous to tissues outside thetumor. Tumor cells take up and use the phosphorous rapidly, selectivelykilling them with radioactivity without damaging normal cells in otherparts of the body. By the time the capillaries become unclogged, all ormost of the radioactive phosphorous has been absorbed by the cellscomprising the tumor, leaving little to escape into adjacent tissue.This therapy, however, is difficult to implement and always carries thedanger of radioactive material escaping into healthy parts of the bodycausing serious damage.

Robert T. Gordon in U.S. Pat. No. 4,622,952 disclosed a different methodfor treating tumors. This method attempts to take advantage of theobserved different heat sensitivity between tumor and normal cells. Itis well known that tumor cells are killed at lower temperatures thannormal cells. Thus, Gordon proposed a method using electromagneticenergy to elevate the temperature of tumor cells or tissues, to kill thetumor cells without seriously affecting normal cells.

Immunotherapy

1. Antibody Response

Many attempts have been made to kill tumor cells with polyclonal ormonoclonal isoantibodies or autologous antibodies elicited againsttumor-specific antigens. Generally, this method is not successful,especially when dealing with solid tumors.

2. Cytotoxic Immunity

Unfortunately, these approaches for the prevention and/or treatment ofcancer have not been successful or completely satisfactory because of anumber of problems, such as the absence in the vaccine of tumor antigensexpressed by the tumor to be treated, poor characterization of theantigens in tumor vaccines, the contamination of vaccines by immunogenicbut undesirable material, such as fetal calf serum (FCS) protein ortransplantation antigens and additionally due to the antigenicheterogenicity of the cancer cells. Moreover, such tumor vaccines wereoften prepared from fresh tumor cells, the supply of which is limited sothat the properties of the vaccines are not reproducible.

3. Current Concepts

Selecting an Aspecific Target Substance.

U.S. Pat. No. 5,658,234, issued to Dunlavy in 1997 describes a methodfor treating a tumor comprising the steps of selecting a targetsubstance which has at least one component with an atomic or molecularresonance frequency or frequencies different from the atomic, molecularor cellular resonant frequencies of normal cells, locating or depositingthe target substance within the tumor, and irradiating the targetsubstance with electromagnetic wave energy at a frequency or frequenciescorresponding to the atomic or molecular resonance of the component suchthat the component absorbs energy from the electromagnetic wave,resulting in the release of heat sufficient to destroy, terminate orslow the growth of the tumor without adversely affecting the viabilityof normal cells.

a. Specific Melanoma Antigens

Melanosomal antigens can be recognized by the immune system. This hasbeen demonstrated by immunoprecipitation of a gp75 antigen fromautologous melanoma cells by serum IgG antibodies of a patient withmetastatic melanoma (Mattes, J. M., T. M. Thomson, L. J. Old, and K. O.Lloyd. (1983) A pigmentation associated, differentiation antigen ofhuman melanoma defined by a precipitating antibody in human serum, Int.J. Cancer. 32:717). The gp75 antigen is a melanosomal polypeptide thatis the most abundant glycoprotein synthesized by pigmented melanocytesand melanomas. (Tai, T., M. Eisinger, S. Ogata, and K. O. Lloyd. (1983)Glycoproteins as differentiation markers in human malignant melanoma andmelanocytes, Cancer Res. 43:2773). Epidermal melanocytes, benignpigmented lesions, and primary and metastatic melanomas express gp75,but other cell types do not (Thomson, T. M., F. X. Real, S. Murakami, C.Cardon-Cardo, L. J. Old, and A. N. Houghton. (1988) Differentiationantigens of melanocytes and melanoma: Analysis of melanosome and cellsurface markers of human pigmented cells with monoclonal antibodies, J.Invest. Dermatol. 90:459). In the present invention, it is demonstratedthat gp75 cDNA had approximately 90% identity with the derived aminoacid and nucleotide sequences of a mouse gene that maps to the b (brown)locus. The brown locus is a site that determines coat color andinfluences the type of melanin synthesized, suggesting that gp75 mayregulate or influence the type of melanin synthesized.

The fact that IgG antibodies in sera of a patient with metastaticmelanoma have been shown to immunoprecipitate gp75 demonstrates thatimmunological tolerance against gp75 can be broken. This inventiontherefore provides expression vectors comprising gp75 cDNA for use as avaccine against melanoma, whereby the amino acid sequences of peptideswere determined from gp75 polypeptide, which was isolated and purifiedby the mouse monoclonal antibody TA99, and whereby cDNA clones wereisolated by screening with oligonucleotides based on the peptidesequences.

b. Human Prostatic Specific Reductase.

U.S. Pat. No. 6,106,829, issued to He, et al. uses a human prostaticspecific reductase polypeptide as a diagnostic marker for prostatecancer and as an agent to determine if the prostate cancer hasmetastasized. The patent also discloses antibodies specific to theprostatic specific reductase polypeptide that may be used to targetprostate cancer cells and be used as part of a prostate cancer vaccine.

c. Telomerase

Another method for treating tumors currently being evaluated by medicalresearchers makes use of a substance called telomerase, an enzyme thattumor cells produce and require to remain alive, but which normal bodycells (except for sperm and hematopoietic system) neither produce norrequire. This unique property of telomerase has prompted attempts todevelop a drug that will block the action of the enzyme sufficiently toeither inhibit the growth of new tumor cells or cause the death of olderones. Telomerase is an example of a class of substances that are oftenreferred to as being “tumor-specific” because they are needed and/orused by tumor cells in differentially larger amounts than by normalhealthy cells of the body.

Telomeres, the protein-DNA structures physically located on the ends ofthe eukaryotic organisms, are required for chromosome stability and areinvolved in chromosomal organization within the nucleus (See e.g.,Zakian, Science 270:1601 [1995]; Blackburn and Gall, J. Mol. Biol.,120:33 [1978]; Oka et al., Gene 10:301 [1980]; and Klobutcher et al.,Proc. Natl. Acad. Sci., 78:3015 [1981]). Telomeres are believed to beessential in such organisms as yeasts and probably most othereukaryotes, as they allow cells to distinguish intact from brokenchromosomes, protect chromosomes from degradation, and act as substratesfor novel replication mechanisms. Telomeres are generally replicated ina complex, cell cycle and developmentally regulated, manner by“telomerase,” a telomere-specific DNA polymerase. However,telomerase-independent means for telomere maintenance have beendescribed. In recent years, much attention has been focused ontelomeres, as telomere loss has been associated with chromosomal changessuch as those that occur in cancer and aging.

Importantly, telomere replication is regulated both by developmental andcell cycle factors. It has been hypothesized that aspects of telomerereplication may act as signals in the cell cycle. For example, certainDNA structures of DNA-protein complex formations may act as a checkpointto indicate that chromosomal replication has been completed (See e.g.,Wellinger et al., Mol. Cell. Biol., 13:4057 [1993]). In addition, it hasbeen observed that in humans, telomerase activity is not detectable inmost somatic tissues, although it is detected in many tumors (Wellinger,supra). This telomere length may serve as a mitotic clock, which servesto limit the replication potential of cells in vivo and/or in vitro.What remains needed in the art is a method 25 to study the role oftelomeres and their replication in normal as well as abnormal cells(i.e., cancerous cells). An understanding of telomerase and its functionis needed in order to develop means for use of telomerase as a targetfor cancer therapy or anti-aging processes.

Despite the wide-ranging and expensive efforts expended in researching,developing and evaluating new treatments and cures for tumors andcancers, no truly significant advances or completely satisfactorytreatments have thus far been achieved.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a noveland effective treatment modality for both benign and malignant tumors.The treatment must avoid the disadvantages and dangers of the priortreatments discussed above, especially with respect to the use ofradioactive substances and chemotherapy.

Another object of the present invention contemplates the ability toconstruct a vaccine that is universally effective against anyproliferating tumor.

To achieve these objectives, a most preferred embodiment of thisinvention is a universal vaccine for treating tumors of any origin,having at least one telomerase reverse transcriptase (hTRT) peptide inan amount effective for initiating and enhancing a cytotoxic Tlymphocyte (CTL) response against mammalian cancer cells in aphysiologically acceptable carrier. Preferably, the telomerase peptideis modified to enhance binding to a major histocompatibility complex(MHC) molecule.

The MHC molecule may advantageously be a Class I human leucocyte antigen(HLA), for example, HLA-A2. Preferably, the hTRT peptide is a synthetichuman telomerase reverse transcriptase peptide, but it may also be aneffective synthetic homologue. Preferably, the peptide is from about 7to about 15 amino acid residues in length, and most preferably, a 9mer.It may be effective either alone or in combination with other peptides.

The vaccine preparation described hereinabove may also comprise anadjuvant or facilitator. One highly preferred facilitator is aninterleukin molecule. Also contemplated by this invention, is asynthetic hTRT peptide advantageously restricted by a Class I majorhistocompatibility complex (MHC) molecule.

Another object of the invention is a method for inducing and enhancing aCTL response against cancer cells. This method comprises harvestingmammalian blood leucocytes, pulsing the leucocytes with an effectiveamount of hTRT, and contacting cancer cells with an effective amount ofpulsed leucocytes. This contacting may be accomplished in vitro or invivo. The method, in its simplest form, can be used in vitro fordetermining whether a cancer patient has potential immunity against histumor, and is a likely candidate for treatment.

Yet another object of this invention contemplates a method for targetingcytotoxic lymphocytes (CTL) to tumor cells by administering an effectiveamount of telomerase reverse transcriptase (TRT) peptide to a mammalianrecipient, which amount is effective to attract CTL to the tumor cells.The recipient preferably is a cancer patient.

These objects and other aspects and attributes of the present inventionwill become increasingly clear upon reference to the following drawingsand accompanying specification.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Induction of CTL against hTRT in peripheral blood leucocytes(PBMC) from normal blood donors. T cells from HLA-A2+ individuals werestimulated by autologous PBMC pulsed with hTRT-derived syntheticpeptides as detailed in the Material and Methods. (A). Results refer toeffector cells from individual donors immunized in vitro against p540(SEQ ID NO:01). Open circles define T2 cells and closed circles T2 cellspulsed with p540 (SEQ ID NO:01) as targets. (B). Results refer toeffector cells from individual donors immunized in vitro against p865(SEQ ID NO:02). Open diamonds define T2 cells and closed diamonds T2cells pulsed with p865 (SEQ ID N02) as targets. Effector to targetratios are indicated on an individual basis. Percent cytotoxicity wascalculated as specified in The Materials and Methods.

FIG. 2. Induction of CTL against hTRT in PBMC from prostate cancerpatients. (A). Results refer to effector cells from individual patientsimmunized against p540. Values refer to cells tested after three roundsof in vitro stimulation. Open circles define T2 cells and closed circlesT2 cells pulsed with p540 as targets. (B). Results refer to effectorcells from individual patients immunized against p865. Open diamondsdefine T2 cells and closed diamonds T2 cells pulsed with p865 astargets. Effector to target ratios are indicated on an individual basis.(C). Results refer to effector cells from individual patients immunizedin vitro against p540 (circles) or p865 (diamonds). Open symbols definethe HLA-A2-PC-3 prostate cancer cell line as a target. Closed symbolsdefine the HLA-A2+ prostate cancer cell line LnCap as a target. Percentcytotoxicity was calculated as specified in the Materials and Methodssection.

FIG. 3. Molecular specificity of target recognition by CTL generatedagainst hTRT peptides. (A). Cold target inhibition. ⁵¹Cr-labeled LnCapcells (5×10⁴ cells/ml) were mixed with T2 cells (open symbols) or T2cells pulsed with p540 (closed circles) or p865 (closed diamond) (1μg/ml) at a cold:hot target cell ratio of 5:1, 25:1 and 50:1. Patients'CTL lines 380.540.1 and 380.865.1 generated against p540 and p865,respectively, were added at an E:T ratio of 50:1. (B) Lysis of T2 cellspulsed with irrelevant HLA-A2 binding peptides. Results refer to lysisby patients' (#651) CTL generated against p540 (panel a) or p865 (panelb), and patients' (#380) CTL generated against p540 (panel c) or p865(panel d). Closed symbols define T2 cells pulsed with p540 (circles),p865 (diamonds) and MART-1 peptide (triangles). Open circles refer tonon-pulsed T2 cells. Percent cytotoxicity was calculated as specified inThe Material and Methods.

FIG. 4. Prostate cancer patients' CTL against hTRT are MHC Class Irestricted. Patient CTL lines 380.540.1 and 380.865.1 were tested in a⁵¹Cr-release assay using as targets T2 cells pulsed with p540 (A) orp865 (B). The following inhibitory antibodies were used: murinemonoclonal antibody BB7.2 (IgG2b) against MHC 15 Class I, murinemonoclonal antibody Q5/13 (IgG2a) against HLA-DR, and the engineeredantibody 1RGD3 that blocks NK cell function.

FIG. 5. Human Telomerase Reverse Transcriptase (hTRT) sequence (SEQ IDNO:23) [from Nakamura et al., 1997]

FIG. 6. Normal blood donor PBMC immunized in vitro against p572(Y)peptide of hTRT generate CTL that kill melanoma cells 624. The resultsare expressed as percent lysis and show by comparison lysis of 624melanoma cells, and HLA-A2+T2 target cells pulsed with the p572(Y) andp572 wild type peptides, respectively. Nonspecific lysis of T2 cells isshown as a control.

FIG. 7 shows an exemplary diagram of the interaction between a cancercell, T-cell and killer cells.

DESCRIPTION OF THE PREFERRED EMBODIMENT

As used herein, the terms “telomerase” and “telomerase complex” refer tofunctional telomerase enzymes. It is intended that the terms encompassthe complex of proteins found in telomerases. For example, the termsencompass the 123 kDa and 43 kDa telomerase protein subunits.

Telomerase is a ribonucleoprotein enzyme which has been linked tomalignant transformation in human cells. Telomerase activity isincreased in the vast majority of human tumors making its gene productthe first molecule common to all human tumor The generation ofendogenously-processed telomerase peptides bound to Class I majorhistocompatibility complex (MHC) molecules could therefore targetcytotoxic T lymphocytes (CTL) to tumors of different origins. This couldadvance vaccine therapy against cancer provided that precursor CTLrecognizing telomerase peptides in normal adults and cancer patients canbe expanded through immunization. Applicant demonstrates here that themajority of normal individuals and patients with prostate cancerimmunized in vitro against two HLA-A2.1 restricted peptides (p540 setforth as SEQ ID NO:1; and p865 set forth as SEQ ID NO:2) from telomerasereverse transcriptase (hTRT), develop hTRT specific CTL. This suggeststhe existence of precursor CTL for hTRT in the repertoire of normalindividuals and in cancer patients. Most importantly, cancer patients'CTL specifically lysed a variety of HLA-A2+ cancer cell lines,demonstrating immunological recognition of endogenously-processed hTRTpeptides. Moreover, in vivo immunization of HLA-A2.1 transgenic micegenerated a specific CTL response against both hTRT peptides. Based onthe induction of CTL responses in vitro and in vivo, and thesusceptibility to lysis of tumor cells of various origins by hTRT CTL,Applicant suggests that hTRT could serve as a universal cancer vaccinefor humans.

INTRODUCTION

Telomerase is a unique ribonucleoprotein that mediates RNA-dependentsynthesis of telomeric DNA (1), the distal ends of eukaryoticchromosomes that stabilize the chromosomes during replication (2, 3).When activated, telomerase synthesizes telomeric DNA and compensates forits loss with each cell division (4). Since telomeres shortenprogressively with successive cell divisions, telomere length isconsidered to mirror the replicative history of cell lineage (5) andcell population dynamics (6, 7). In mice, telomerase appears to play anessential role in the long-term viability of high-renewal organ systemssuch as the reproductive and haemopoietic systems (8).

Maintenance of a constant telomere length ensures chromosomal stability,prevents cells from aging, and confers immortality (9-11). Mice lackingtelomerase RNA show that telomerase activation is a key event inmalignant cell transformation (8, 12, 13). In humans, in vitro studiesshow that the long-term ectopic expression of telomerase reversetranscriptase (hTRT) in normal fibroblasts is sufficient forimmortalization but not malignant transformation (14). However, theexpression of hTRT in combination with two oncogenes (SV40 T antigen andRas) promotes tumor transformation in normal human epithelial andfibroblast cell lines (15). These transformed cells form tumors in nudemice. Thus, although telomerase per se is not tumorigenic, it plays adirect role in oncogenesis by allowing pre-cancerous cells toproliferate continuously and become immortal. The PCR-based TRAP assay(16) reveals a striking correlation (>80%) between high telomeraseactivity and tumors of different histological origins and types (17,18). In contrast, normal tissues display little or no telomeraseactivity (18, 19). Therefore, telomerase expression in tumors is muchgreater than HER2/neu and mutated P53, which range between 30% and 50%respectively (20, 21). From the foregoing, it is reasonable thatexpression of hTRT in cancer cells is a likely source of peptides that,upon association with major histocompatibility complex (MHC) Class Imolecules, could target cytotoxic T lymphocytes (CTL) to cancer cells.An interesting analogy exists with HIV-1 reverse transcriptase, anenzyme similar to hTRT, which gives origin to peptide/MHC Class Icomplexes that target CTL responses to virus infected cells (22). Thus,since high telomerase activity is widespread among human tumors, hTRTcould serve as a universal tumor antigen for immunotherapy and vaccineapproaches.

hTRT is encoded in the genome and is in all respects a self antigen.Consequently, CD8+ T lymphocytes with a receptor for MHC/hTRT peptidecomplexes are expected to be eliminated during thymic negativeselection, reducing the potential precursor T cell repertoire andimposing limitations on their expansion upon encounter with tumor cellsin adult life. Additionally, stimulation by antigen in the absence of asecond signal induces clonal anergy (23), further hampering thepotential repertoire. The extent to which these events affect the normaladult repertoire, and whether or not exposure to hTRT during cancerformation has any adverse effect on the ability of cancer patients torespond, is not known. Because answering these questions is relevant tofuture strategies of immune intervention targeted at hTRT, the abilityof normal individuals and cancer patients to mount a CTL response invitro against two hTRT peptides restricted by the HLA-A2 allele wasanalyzed.

MATERIALS AND METHODS Example 1 Synthetic Peptides

hTRT synthetic peptides p540 (5401LAKFLHWL548, SEQ ID NO:1), p865(865RLVDDFLLV873, SEQ ID NO:2) and MART-1 (27AAGIGILTV35, SEQ ID NO:3)were purchased from the Biopolymer Synthesis Center (CalTech, Pasadena,Calif.). Synthetic peptides 128TPPAYRPPNAPIL140 (SEQ ID NO:4) of thehepatitis B core antigen (HBVc), 571YLSGANLNL579 (SEQ ID NO:5) ofcarcinoembryonic antigen (CEA), 476VLYRYGSFSV486 (SEQ ID NO:6) ofmelanoma antigen gp100, 4761LKEPVHGV484 (SEQ ID NO:7) of HIV-1 reversetranscriptase were purchased from Neosystem (Strasburg, France).

Human Blood Cells

Buffy coats from normal donors were purchased from the San Diego BloodBank. HLA-A2+ individuals were selected by FACS screening usingmonoclonal antibody BB7.2. Prostate cancer patients were recruitedthrough the Division of Urology (University of California, San Diego).Blood from these patients was obtained by venipuncture. HLA-A2+individuals were selected by FACS screening using monoclonal antibodyBB7.2. Blood collection and experiments were performed in accordancewith an approved IRB.

Tumor Cell Lines

T2 cells were a kind gift of Dr. Peter Creswell (Yale University).Melanoma cell lines 624 and 1351 were the kind gift of Dr. JohnWunderlich (National Cancer Institute, Bethesda, Md.). Prostate cancercell lines LnCap and PC-3 were the kind gift from Dr. Antonella Vitiello(PRI Johnson, La Jolla Calif.). Breast, colon and lung tumor cell lineswere obtained from ATCC, Rockville, Md.

Example 2 In Vitro Immunization

PBMC were separated by centrifugation on Ficoll-Hypaque gradients andplated in 24-well plates at 5×10⁵ cells/ml/well in RPMI-1640supplemented with 10% human AB+ serum, L-glutamine and antibiotics (CM).Autologous PBMC (stimulators) were pulsed with hTRT synthetic peptidesp540 or p865 (10 μg/ml) for 3 hours at 37° C. Cells were then irradiatedat 5000 rads, washed once, and added to the responder cells at aresponder:stimulator ratio ranging between 1:1 and 1:4. The next day, 12IU/ml IL-2 (Chiron Co., Emeryville, Calif.) and 30 IU/ml IL-7 (R&DSystems, Minneapolis, Minn.) were added to the cultures. Lymphocyteswere re-stimulated weekly with peptide-pulsed autologous adherent cellsas follows. First, autologous PBMC were incubated with hTRT peptide (10μg/ml) for 3 hours at 37° C. Non-adherent cells were then removed by agentle wash and the adherent cells were incubated with fresh mediumcontaining the hTRT peptide (10 μg/m) for an additional 3 hours at 37°C. Second, responder cells from a previous stimulation cycle wereharvested, washed and added to the peptide-pulsed adherent cells at aconcentration of 5×10⁵ cells/ml (2 ml/well) in medium without peptide.Recombinant IL-2 and IL-7 were added to the cultures on the next day.

Example 3 In Vivo Immunization

HHD mice were immunized subcutaneously at the base of the tail with 100μg of individual hTRT peptide emulsified in incomplete Freunds' adjuvant(IFA). Half of the mice were immunized with the hTRT peptide and 140 μgof the helper peptide TPPAYRPPNAPIL (SEQ ID NO:4), which corresponds toresidues 128-140 of the hepatitis B core antigen (HBVc) (25).

Example 4 HLA-A2.1 Binding/Stabilization Assay

The relative avidity was measured as previously described (25). Briefly,T2 cells were incubated overnight at 37° C. in RPMI supplemented withhuman β2-microglobulin (100 ng/ml) (Sigma, St. Louis, Mo.) in theabsence (negative control) or presence of the test peptide or thereference peptide 4761LKEPVHGV484 (SEQ ID NO:7) of HIV-1 reversetranscriptase at various final peptide concentrations (0.1-100 μM).Cells were incubated with Brefeldin A (0.5 μg/ml) for one hour andsubsequently stained with a saturating concentration of monoclonalantibody BB7.2 for 30 minutes at +4° C. followed by washing and a secondincubation with a goat antibody to mouse Ig (Fab′)2 conjugated to FITC(Caltag, South San Francisco). Cells were then washed, fixed with 1%paraformaldehyde and analyzed in a FACs Calibur cytofluorimeter (Becton& Dickinson, San Jose, Calif.). The mean fluorescence intensity of eachconcentration minus that of cells without peptide was used as anestimate of peptide binding. Results are expressed as values of RA,which is the ratio of the concentration of test peptide necessary toreach 20% of the maximal binding by the reference peptide over that ofthe reference peptide so that the lower the value the stronger thebinding. Dissociation of the test peptide from the HLA-A2.1 moleculereflects the half-life of fluorescence intensity of the peptide/MHCcomplex over time. The half-life of the complex (DC50) refers to thetime (hours) required for a 50% reduction of the TO mean fluorescenceintensity (25). Synthetic peptides 571YLSGANLNL579 (SEQ ID NO:5) ofcarcinoembryonic antigen (CEA) and 476VLYRYGSFSV486 (SEQ ID NO:6) ofmelanoma antigen gp100 were used as internal controls to account forinter-tests variability and for consistency with previously reported RAand DC50 measures (25).

Example 5 Cytotoxicity Assay

(a) The induction of CTL in human PBMC was monitored in a conventional⁵¹Cr-release assay. Briefly, peptide-pulsed TAP-/HLA-A2.1+ human T2cells were incubated with 10 μg of hTRT peptides or with the MART-1control peptide for 90 minutes during labeling with ⁵¹Cr. After washing,the target cells were added to serially diluted effectors in 96-wellmicroplates. After a 6 hour incubation period at 37° C., supernatantswere harvested and counted in a Trilux Betaplate counter (Wallac, Turku,Finland). Results are expressed as the percentage (%) of specific lysisand determined as follows: [(experimental cpm−spontaneous cpm)/(maximumcpm spontaneous cpm)]×100. (b) The induction of CTL in HHD mice wasassessed as follows. Spleen cells were harvested 7 days afterimmunization and were restimulated in vitro with the corresponding hTRTpeptide and LPS (25 μg/ml)-stimulated irradiated (5000 rads) syngeneicspleen cells. After six days of culture the cells were harvested andtested for their ability to lyse HHD-transfected/TAP-RMA-cells in a 4hour ⁵¹Cr-release assay (25). Specific lysis was calculated as indicatedin the legend of FIG. 1. Values refer to maximal cytotoxicity measuredfor individual responder mice at an effector to target ratio of 60:1.

RESULTS Example 6 Identification and Analysis of HLA-A2.1-RestrictedhTRT Peptides

The amino acid sequence of hTRT (locus AF015950) (19) was analyzed for9mer peptide sequences containing known binding motifs for the HLA-A2.1molecule [52; 35; 60], a subtype encompassing 95% of HLA-A2 allele,which is expressed in about 50% of the Caucasian population (26-28).Peptides were identified by reverse genetics based on canonical anchorresidues for HLA-A2.1 (29), and by using the software of theBioinformatics & Molecular Analysis Section (NIH) websitebimas.dcrt.nih.gov/molbio/hla_bind/index.html, which ranks 9mer peptideson a predicted half-time dissociation coefficient from HLA Class Imolecules (30). From an initial panel of 30 candidate peptides Applicantretained two sequences, 5401LAKFLHWL548 (SEQ ID NO:1) and865RLVDDFLLV873 (SEQ ID NO:2), denoted hereunder as p540 and p865.

Since the immunogenicity of MHC Class I-restricted peptides reflects tosome degree their binding and stabilizing capacity for MHC Class Imolecules (31-33) Applicant sought direct proof of the strength ofinteraction between the two hTRT peptides and the HLA-A2.1 molecule in aconventional binding/stabilization assay that uses theantigen-transporting deficient (TAP-) HLA-A2.1+ human T2 cells. Therelative avidity (RA) calculated in reference to 4761LKEPVHGV484 (SEQ IDNO:7) of HIV-1 reverse transcriptase, a canonical high binder peptide(25), was 2.9 and 2.5 for p540 and p865, respectively (Table I). Thestability of each peptide bound to HLA-A2.1 was measured as thehalf-life of the complex

TABLE I Peptide origin/ Relative Avidity designation Sequence (RA)^(a)DC50^(b) hTRT p540 ILAKFLHWL 2.9 4-6 (SEQ ID NO:1) hTRT p865 RLVDDFLLV2.5 2-4 (SEQ ID NO:2) CEA p571^(c) YLSGANLNL 3 >10 (SEQ ID NO:5) gp100p476^(d) VLYRYGSFSV 9 4-6 (SEQ ID NO:6) ^(a)The relative avidity of hTRTpeptides was measured relative to the reference peptide ILKEPVHGV at afinal peptide concentration of 0.1-100 μM. ^(b)DC50 refers to the timerequired for a 50% reduction in mean fluorescence intensity.^(c)Peptides of human carcinoembryonic antigen (CEA) (p571) and humanmelanoma antigen gp100 (p476) were used as internal controls forcomparison with previously reported values³³.(DC50) and was in the order of 4-6 hours for p540 and 2-4 hours forp865, respectively. Collectively, these measurements indicate that bothhTRT peptides are excellent binders to HLA-A2.1 albeit p865 has a fasterdissociation rate.

Example 7

CTL Response Against hTRT in Normal Human Individuals

The presence of precursor T cells for both hTRT peptides and theirexpansion upon antigen stimulation were tested using peripheral bloodlymphocytes (PBMC) of 10 HLA-A2+ normal blood donors in an in vitroimmunization assay. Nine out of 10 individuals responded to immunizationgenerating T cells that lysed peptide-pulsed T2 cells as targetsstarting from the third round of peptide stimulation. All nineresponders generated CTL specific for p540 and seven responded againstp865 (FIGS. 1, A and B). The values of maximal lysis varied fromindividual to individual and ranged between 28-68% and 20-68%,respectively. In two instances (donor 975 and 980) there was a lower butmeasurable non-specific lysis, possibly due to contaminant NK cells.Thus, by random testing of normal HLA-A2+ individuals, it was clearlyestablished that both hTRT peptides are immunogenic, implying thatprecursor CTL for hTRT are present in the peripheral adult repertoire.

Example 8 CTL Response Against hTRT in Cancer Patients

Whether or not CTL against hTRT could also be induced in cancer patientswas studied in four HLA-A2.1+ individuals with clinical and histologicaldiagnosis of prostate cancer. All four patients were refractory tohormonal therapy, three had metastases and none had prostatectomy. Inprostate cancer, the most common cause of cancer in men, high hTRTexpression has been documented in 84% of cases (34). Marked lysis ofpeptide-pulsed T2 cells was observed in 3 out of 4 individuals afterthree rounds of in vitro stimulation (FIGS. 2, A and B). Both peptidesyielded comparable CTL responses in all three individuals with maximallysis ranging between 27-49% and 48-52%, respectively. CTL against bothpeptides lysed LnCap, a HLA-A2.1+ prostate cancer cell line, withmaximal lysis ranging between 24-36% for p540 and 12-40% for p865.Prostate cancer cell line PC-3, which is HLA-A2.1-, was used as controland was not lysed (FIG. 2, C). Both prostate cancer cell lines testedpositive for hTRT by the TRAPeze (telomerase detection assay; INTERGEN)(not shown), suggesting that the CTL generated against the syntheticpeptides might lyse cancer cells by recognizing hTRTpeptide/MHC Class Icomplex at the surface of cancer cells.

Cold target competition experiments were performed in an attempt tounderstand if lysis of the LnCap tumor cell line was specific forendogenously processed hTRT peptides. In these experiments the lysis ofLnCap cells by CTL from a prostate cancer patient was competed for by T2cells pulsed in vitro with p540 or p865 (10 μg/ml). Peptide-loaded T2cells caused a dose-dependent inhibition of lysis of LnCap cells in bothpeptide combinations (FIG. 3, A). Applicant further assessed thespecificity of the CTL generated against each one of the two hTRTpeptides by testing them on T2 targets pulsed with irrelevant HLA-A2binding peptides. Neither T2 cells pulsed with peptide 27AAGIGILTV35(SEQ ID NO:3) from the melanoma antigen MART-1 nor T2 cells pulsed witha non-homologous hTRT peptide were lysed (FIG. 3, B). Collectively,these studies show that 1) patients' CTL are specific for the hTRTpeptide used to induce them, and 2) lysis of prostate cancer cells ismediated by, and is specific for, endogenously-processed hTRT peptidescomplexed with HLA-A2.1 molecules, suggesting chemical identity betweennaturally processed peptides on tumor cells and the synthetic peptidesused for immunization. Formal validation will require elution ofpeptides from tumor cells and their analysis by tandem mass spectrometry(35). Studies on MHC restriction were performed using blockingantibodies. Lysis of peptide-pulsed T2 cells by CTL lines generated froma prostate cancer patient was inhibited by the anti-MHC Class Imonoclonal antibody BB7.2 in both peptide combinations (FIG. 3), but notby the anti-MHC Class II monoclonal antibody Q5/13 (36) nor bytransfectoma antibody 1RGD3 that blocks NK cells (37). By two-color FACSanalysis, the phenotype of T cells proliferating after three rounds ofin vitro stimulation with hTRT peptide was CD3+ (78%), CD8+ (37%), CD4+(36%) and CD16/56 (6%). Collectively, these experiments confirm thateffector T cells generated by in vitro immunization are MHC ClassI-restricted (CD8+) T cells which do not possess NK activity.

hTRT is expressed in normal cells such as circulating B and T cells,germinal center B cells, thymocytes and CD34+ progenitor hemopoieticcells (6, 7, 38). This implies that CTL generated against hTRT peptidescould engender an autoimmune attack on normal cells. To this end,Applicant verified whether cancer patients' CTL would lyse HLA-A2+ CD34+cells. Neither CTL against p540 nor those against p865 induced any lysisover a wide range of effector to target (E:T) ratios (not shown). Thus,at least with respect to hemopoietic stem cells an autoimmune attackappears unlikely. This is consistent with the fact that activated Tcells were not lysed by hTRT CTL in culture.

Example 9 CTL Response Against hTRT in HLA-A2.1-Transgenic Mice

Whether peptides can serve as immunogens in vivo and elicit a CTLresponse depends on a variety of factors such as the mode ofimmunization, suitable activation of antigen presenting cells, thefrequency of precursor cells, and binding and stabilization of MHC ClassI molecules by peptide. In this study Applicant demonstrated (Table I)that both peptides bind to HLA-A2.1 with a RA <3 but possess differentdissociation rates. In either case Applicant was able to generate CTLresponses in vitro from PBMC of normal blood donors as well as prostatecancer patients. Therefore, a reasonable expectation would be that theymay also be immunogenic in vivo. To test this possibility Applicantimmunized H-2 Db−/−, β2m−/−, HLA-A2.1+ monochain transgenic HHD mice(39). In these mice the peripheral CD8+ T cell repertoire is essentiallyeducated on the transgenic human molecule. Therefore, HHD mice are anexcellent tool to assess at the pre-clinical level the ability ofindividual peptides to induce HLA-A2.1 restricted CTL responses in vivo(25).

Both p540 and p865 were able to induce specific CTL responses (Table II)although differences were noted. In fact, p540 induced CTL whether aloneor in combination with a helper peptide (66 vs. 80% responders). Incontrast, a high (70%) response against p865 was obtained only when itsimmunogenicity was increased by association with the helper peptide. Thedifferent immunogenicity of the two hTRT peptides was also reflected bythe magnitude of individual responses (55.8±9.4 vs. 20±11.5% lysis)against p540 and p865 with helper peptide, respectively. This isconsistent with the observation that two normal blood donors respondedto immunization against p540 but failed to respond against p865 (FIG.1). Thus, there is an overall correlation between the results ofbinding/stabilization of the HLA-A2.1 molecule, the results ofimmunogenicity in vitro of human PBMC, and the response in vivo in HHDmice. Finally, to exclude the development of untoward autoimmunity HHDmice immunized against hTRT peptides were monitored with respect to thenumber of circulating B lymphocytes. Using a dual stain (B220 andanti-Ig) FACS analysis Applicant found no decrease in circulating Bcells in immunized mice when compared to normal HHD mice (not shown).Furthermore, no enlarged mesenteric lymph nodes nor cellular infiltratesin the liver were noticed after immunization (not shown).

Example 10 Cancer Patients' CTL Kill Tumor Cells of Various Origins andTypes

Because CTL generated against p540 and p865 recognizenaturally-processed hTRT peptides on LnCap prostate cancer cells andhTRT activity is expressed at high levels in the

TABLE II INDUCTION OF CTL AGAINST HTRT IN HLA-A2.1 TRANS- GENIC MICEhTRT Helper No. Group Peptide Pepticle Responders Percent lysis I5401LAKFLHWL548 − 10/15 (66%) (35, 21, 34, 42, (SEQ ID NO:1) 56, 21, 12,35, 42, 16) II 5401LAKFLHWL548 +  8/10 (80%) (45, 56, 62, 64, (SEQ IDNO:1) 65, 45, 65, 45) III 865RLVDDFLLV873 −  3/15 (20%) (25, 12, 15)(SEQ ID NO:2) IV 865RLVDDFLLV873 +  7/10 (70%) (25, 32, 35, 12, (SEQ IDNO:2) 16, 18, 21) ^(a)HHD mice were immunized by a subcutaneousinjection of 100 μg of hTRT peptide emulsified in incomplete Freunds'adjuvant (IFA). In group 2 and 4 the hTRT peptide was administeredtogether with 140 μg of the helper peptide TPPAYRPPNAPIL (SEQ ID NO:4)(25). ^(b)Values of cytotoxicity refer to individual responder mice.Spleen-derived CTL were harvested 7 days after immunization and thencultured for six days with the homologous hTRT peptide. Values refer tomaximal cytotoxicity at an effector to target ratio of 60:1.vast majority of human cancers, recognition of hTRT-derived peptides byCTL could mediate killing of a wide variety of cancer types. CTL linesfrom a prostate cancer patient were used in a ⁵¹Cr-release assay toassess lysis of HLA-A2+ tumor cell lines of breast, colon, lung, andmelanoma origin as targets. By the TRAPeze assay all these cell lineswere hTRT positive. Peptide-pulsed T2 cells and LnCap prostate cancercell line served as positive controls (Table III). All cell lines butthe SW480 colon cell line were lysed by CTL generated against p540(range lysis 39-48%). On the other hand, all cell lines but the H69 lungcell line were lysed by CTL generated against p865 (range lysis 37-41%).The cytotoxic activity was dependent on expression of the HLA-A2molecule since tumor-matched cell lines of a different HLA type were notlysed. Collectively, these data indicate that hTRT peptides such as p540and p865 are naturally-processed in a variety of tumor cell types.

The antigen-recognition activity of T cells is intimately linked withrecognition of MHC (HLA in humans) molecules. This complex is located onchromosome 6, and encompasses nearly 200 genes encoding for MHC class Iand class II among others. The initial discovery is in relation to theHLA-A2 allele, which is expressed in about 50% of the Caucasianpopulation (56). About 95% of HLA-A2+ white individuals express theHLA-A2.1 subtype (53).

The majority of peptides bound to MHC class I molecules have arestricted size of 9±1 amino acids and require free N- and C-terminalends (52; 59; 61). In addition to a specific size, different class Imolecules appear to require a specific combination of usually two mainanchor residues within their peptide ligands (52; 59). In the case ofthe human allele HLA-A2.1, these anchor residues have been described asleucine (L) at position 2 and L or valine (V) at the C-terminal end(52). More recently, Ruppert et al. found that a “canonical” A2.1 motifcould be defined as L or M (methionine) at position 2 and L, V, or I(isoleucine) at position 9 (60).

Additional criteria were used to refine the selection process. Each ofthe non-anchor

TABLE III Percent Lysis^(c) Cell HTRT HLA- CTL CTL Cell Target OriginExpression^(a) A2^(b) p540^(d) 865^(d) T2 + peptide ND Pos. 59 48 T2 NDPos. 11 4 MCF7 Breast Pos. Pos. 39 41 SKBR3 Pos. Neg. 7 9 SW480 ColonPos. Pos. 12 37 HCT011 Pos. Neg. 9 6 H69 Lung Pos. Pos. 41 9 H146 Pos.Neg. 11 5 624 Melanoma Pos. Pos. 48 39 1351 Pos. Neg. 12 6 LncapProstate Pos. Pos. 44 41 Pc3 Pos. Neg. 9 5 ^(a)hTRT expression of thetumor cells was determined by a PCR-based assay (TRAPezeR, Intergen).^(b)Expression of HLA-A2 was measured by flow cytometry using themonoclonal antibody BB7.2. ^(c)Cellular cytotoxicity was measured in a⁵¹Cr-release assay at an effector to target ratio of 50:1. All tumorcell lines were incubated with 100 IU/ml of recombinant IFN-γ for 48hours before the ⁵¹Cr-release assay. ^(d)Patient's CTL lines 380.540.1and 380.865.1 were generated by immunization with p540 and p865,respectively.residues (position 1, 3, 4, 5, 6, 7, 8) has significant effect of theA2.1 binding (60). More specifically, some amino acids at position 1, 3,6, 7, and 8 virtually abolish A2.1 binding capacity of peptides (60).Therefore, Applicant excluded all peptides with the following aminoacids at the position specified: D (aspartate) and P (proline) atposition 1; K (lysine) at position 3; R (arginine) or G (glycine) atposition 6; and E (glutamate) at position 7 or 8. Through this selectionApplicant excluded 12 and retained 27 peptides. By taking into accountthe frequency of each amino acid in each of the non-anchor positions formany 9mer peptides (60) Applicant defined a more accurate A2.1 bindersand 10 out of the 27 peptides (Table IV):

TABLE IV HTRT-DERIVED HLA-A2.1-RESTRICTED PEPTIDES Anchor Position SEQAnchor Position SEQ Anchor Position SEQ L at position 2 ID L at position2 ID M at position 2 ID V at position 9 NO: L or I at position 9 NO: V,L or I at position 9 NO: ¹⁵²LLARCALFV¹⁶⁰ 8  ⁹⁶VLAFGFALL¹⁰⁴ 9⁸¹²FMCHHAVRI⁸²⁰ 17 ⁸⁶⁵RLVDDFLLV⁸⁷³ 2  ⁶⁷⁵LLGASVLGL⁶⁸³ 10 ⁷²⁴RLTEVIASI⁷³² 11  ⁷⁹⁷SLNEASSGL⁸⁰⁵ 12  ⁸³⁶ILSTLLCSL⁸⁴¹ 13 ⁹²⁶GLFPWCGLL⁹³⁴ 14 ¹⁰⁷²WLCHQAFLL¹⁰⁸⁰ 15  ⁵⁷²RLFFYRKSY⁵⁸⁰ 16

The peptide selection was confirmed using the application availableonline at the web site of the Bioinformatics & Molecular AnalysisSection of the NIH that ranks potential 9 mer peptides based on apredicted half-time dissociation from HLA class I molecules deduced from(58). In our pilot studies one of the peptides identified using the“manual” appmach-P865-(SEQ ID NO:02) ranked among the top 5HLA-A2-binding peptides identified through the software-guided analysis.Another peptide-P540-(SEQ ID NO:01) ranked at the top in thesoftware-guided analysis.

Applicant used two such peptides 5401LAKFLHWL549 (SEQ ID NO: 1) and865RLVDDFLLV873 (SEQ ID NO:2), denoted as p540 and p865. Both peptidesare able to induce a CTL response in vitro in normal blood donors and inpatients with prostate cancer. Applicant has demonstrated that the samepeptides are also able to induce a CTL response in vitro in patientswith melanoma. A synopsis of these studies is shown in Table V.

Collectively, it appears that p540 induced a CTL response in 3 out of 4HLA-A2+ patients. P865 induced a response in two patients only. Itshould be noted that patient 00 was concomitantly being immunized withdendritic cells+melanoma peptides (peptides other than hTRT peptides)and had a high background making it difficult to decided whether aspecific response to hTRT had been induced.

TABLE V INDUCTION OF CTL IN VITRO IN PATIENTS WITH MELANOMA Patient CodeCTL to p540 CTL to p865 Comments 28-7 50% 14% 00 <5% <5% Concomitantlyimmunized with DC; High background 66-5 49%*  1% *Measurable NK activity(17%) 22-1 40% 43%

Additional new findings came from exploring the immunogenicity of otherhTRT peptides. In particular, three peptides were tested whose sequencein the native hTRT molecules is shown below in Table VI:

TABLE VI ADDITIONAL SEQUENCE OF WILD TYPE AND MODIFIED HTRT PEPTIDESName of Peptide Wild Type Sequence SEQ ID NO: Modified Sequence SEQ IDNO: p152 ¹⁵²LLARCALFV¹⁶⁰ 8 ¹⁵²YLARCALFV¹⁶⁰ 18 p555 ⁵⁵⁵ELLRSFFYV⁵⁶³ 19⁵⁵⁵YELLRSFFYV⁵⁶³ 20 p572  ⁷²RLFFYRKSV⁵⁸⁰ 21 ⁵⁷²YLFFYRKSV⁵⁸⁰ 22

Unlike p540, which was characterized as having a high affinity binding(slow half time dissociation) to HLA-A2 (Table VII), these peptides havean estimated half time dissociation score faster than prototype p540.Calculations were made using the program on the “bimas” section of theNIH web site.

Applicant then proceeded to add a single residue (Y) modification inposition 1, which is supposed to increase the binding affinity to HLA-A2and also its immunogenicity (60). The new modified sequences are shownin Table VI.

PBMC from three normal HLA-A2+ individuals were immunized with theY-modified peptides. The results are summarized as follows (Table VII).

CTL generated against p572 were also able to lyze the hTRT+/HLA-A2+melanoma cell line 624. The dose response curve of killing of melanoma624 is shown in FIG. 6. The antigen-recognition activity of T cells isintimately linked with recognition of MHC (HLA in humans) molecules.

DISCUSSION

Applicant has demonstrated that hTRT peptides can expand precursor CTLin PBMC of normal individuals and patients with prostate cancer, andinduce in both instances MHC Class I-restricted, peptide-specific CTLresponses.

TABLE VII THE IMMUNOGENIC CAPABILITY OF “Y” MODIFIED HTRT PEPTIDES. CTLAgainst Target Cells pulsed With . . . Donor Immunogen p152(Y) p555(Y)p572(Y) p572 wild type 218 p152(Y) 7% p555(Y) 4% p572(Y) 48-50% 26-46%219 p152(Y) 2% p555(Y) 8% p572(Y)  4% 222 p152(Y) 1% p555(Y) 1% p572(Y)27% 5%

Therefore, the first major implication from these findings is that theavailable CTL repertoire for hTRT is similarly preserved not only innormal individuals as recently reported (24) but also, and moreimportantly, in individuals with cancer. This suggests that exposure tocancer does not cause deletion or anergy of clonotypes specific forhTRT. Since the three patients responding to immunization were resistantto hormone therapy and had metastases, it was surprising that hTRT CTLcould be induced at such an advanced stage of disease generallycharacterized by immunosuppression. Based on these considerations, onecould predict that since the frequency of precursors from PBMC is highenough to permit their expansion in vitro and because hTRT peptides bindto MHC Class I with sufficient avidity, the two peptides identified inthis study may be used for vaccination of HLA-A2+ cancer patients.

The finding that prostate cancer patients' CTL mediate efficient lysisof a variety of HLA-A2+ cancer cells such as prostate, breast, colon,lung and melanoma is unprecedented. Based on the values of specificlysis it appears as if these cancer cells are equally effective inprocessing and presenting the same endogenous hTRT peptides. Therefore,a second major implication of our study is that similar hTRT peptidesare expressed and complexed with MHC Class I molecules on a variety ofcancer cells of different histological origins and types. This rendersthem susceptible to destruction by CTL and underscores the potentialadvantage hTRT immunization may have in the control of primary tumorsand metastases in a large variety of cancer types in humans.

The future of hTRT-based vaccination will also depend on the type ofside effects that may follow immunization. Since hTRT is expressed instem cells and mature hemopoietic cells (6, 7, 38), the possibilityexists that hTRT vaccination could result in autoimmunity anddestruction of normal cells. In our hands cancer patients' CTL specificfor either p540 or p865 failed to lyse HLA-A2+ CD34+ cells. Similarly,CTL against p540 raised in normal individuals did not lyse HLA-A2+ CD34+cells (24). Together with the lack of overt autoimmune defects inhemopoietic cells and in the liver in HHD mice following vaccinationwith hTRT peptides, Applicant provisionally concludes that CTL specificfor hTRT are unlikely to trigger autoimmunity against normal cells.Possibly, the quantity of hTRT peptides generated under physiologicallineage/clonotype activation and differentiation is insufficient tomediate lysis by CTL. Whether the same holds true for germ cells ofreproductive organs for which little is known about CD8 T cell mediatedautoimmunity, can only be speculated. While additional experiments areneeded, the fact that autoimmunity does not develop after immunizationagainst tumor antigens shared by normal tissues (48, 49), including thelymphoid tissue (50) and reproductive organs (51), supports the viewthat hTRT-based vaccination in cancer patients may be possible and safe.

Methods to implement such hTRT-based vaccination will include thevariety of methods currently in use, such as synthetic peptides,synthetic peptides in immunological adjuvant, dendritic cells pulsedwith synthetic peptides, naked DNA and RNA. In addition, Applicantanticipates that effective vaccination can be achieved using transgeniccells. For instance, genes under a specific lymphocyte promoter can beengineered to code for desired hTRT peptides, transfected and expressedin lymphocytes from an individual (e.g., a cancer patient), and thepatient's own lymphocytes can be used for vaccination, since lymphocytesprocess and present peptides to T lymphocytes, hence effectingvaccination.

In conclusion, based on the demonstration that precursor CTL specificfor two hTRT peptides can be expanded in patients with cancer, their CTLrecognize the same hTRT peptides on tumor cells of various origins andhistological types, and a strong in vivo CTL response against both hTRTpeptides was induced in HLA-A2.1+ monochain transgenic mice, Applicantsuggests that hTRT can be regarded as a universal cancer, antigen andits peptides as the substrate for a possible universal cancer vaccinefor humans.

In accordance with the preceding explanation, variations and adaptationsof the vaccine and methodology of the present invention will suggestthemselves to a skilled practitioner in the medical arts, In the spiritof this invention, these and other possible variations and adaptationsof the present invention, and the scope of the invention, should bedetermined in accordance with the following claims, only, and not solelyin accordance with that embodiment within which the invention has beentaught.

REFERENCES

-   1. Blackburn, E. H. (1992) Ann. Rev. Biochem 61, 113-29.-   2. Blackburn, E. H. (1991) Nature 3 50, 569-73.-   3. Greider, C. W. (1994) Curr. Opin. Oenet. Dvel. 4, 203-11.-   4. Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G.,    Greider, C. W., Harley, C. B. & Bacchetti, S. (1992) EMBO J 11,    1921-9.-   5. Buchkovich, K. J. & Greider, C. W. (1996) Mol. Biol. Cell 7,    1443-54.-   6. Weng, N. P., Levine, B. L., June, C. H. & Hodes, R. J. (1996) J.    Exp. Med. 183, 2471-9.-   7. Weng, N. P., Granger, L. & Hodes, R. J. (1997) Proc. Natl. Acad.    Sci. USA 94, 10827-32.-   8. Lee, H. W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., 2nd,    Greider, C. W. & DePinho, R. A. (1998) Nature 392, 569-74.-   9. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B.,    West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E.,    Weinrich, S. L. & Shay, J. W. (1994) Science 266, 2011-5.-   10. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W.,    Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L.,    Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A. &    Weinberg, R. A. (1997) Cell 90, 785-95.-   11. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.    P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S. &    Wright, W. E. (1998) Science 279, 349-52.-   12. Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Gottlieb, G.    J., Greider, C. & DePinho, R. A. (1999) Cell 96, 701-12.-   13. Greenberg, R. A., Chin, L., Femino, A., Lee, K. H., Gottlieb, G.    J., Singer, R. H., Greider, C. W. & DePinho, R. A. (1999) Cell 97,    515-25.-   14. Morales, C. P., Holt, S. E., Ouellette, M., Kaur, K. J., Yan,    Y., Wilson, K. S., White, M. A., Wright, W. E. & Shay, J. W. (1999)    Nature Genetics 21, 115-8.-   15. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R.    L., Brooks, M. W. & Weinberg, R. A. (1999) Nature 400, 464-8.-   16. Broccoli, D., Young, J. W. & de Lange, T. (1995) Proc. Natl.    Acad. Sci. USA 92, 9082-6.-   17. Shay, J. W. & Bacchetti, S. (1997) Eur. J. Cancer 33, 787-91.-   18. Kim, N. W. (1997) Eur. J. Cancer 33, 781-6.-   19. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L.,    Andrews, W. H., Lingner, J., Harley, C. B. & Cech, T. R. (1997)    Science 277, 955-9.-   20. Marx, J. (1993) Science 262, 1644-5.-   21. Disis, M. L. & Cheever, M. A. (1997) Adv. Cancer Res 71, 343-71.-   22. Walker, B. D., Flexner, C., Paradis, T. J., Fuller, T. C.,    Hirsch, M. S., Schooley, R. T. & Moss, B. (1988) Science 240, 64-6.-   23. Schwartz, R. H. (1990) Science 248, 1349-56.-   24. Vonderheide, R. H., Hahn, W. C., Schultze, J. L. &    Nadler, L. M. (1999) Immunity 10, 673-9.-   25. Firat, H., Garcia-Pons, F., Tourdot, S., Pascolo, S., Scardino,    A., Garcia, Z., Michel, M.-L., Jack, R., Jung, G., Kostmatopoulos,    K., Mateo, L., Suhbrbier, A., Lemonnier, F. &    Langlade-Demoyen, P. (1999) Eur. J. Immunol. 29, 3112-3121.-   26. Lee, T. D. (1990) in The HLA System, ed. Lee, J.    (Springer-Verlag, New York), pp. 141-178.-   27. Fernandez-Vina, M. A., Falco, M., Sun, Y. & Stastny, P. (1992)    Human Immunol. 33, 163-73.-   28. Krausa, P., Brywka, M., 3rd, Savage, D., Hui, K. M., Bunce, M.,    Ngai, J. L., Teo, D. L., Ong, Y. W., Barouch, D., Allsop, C. E. & et    al. (1995) Tissue Antigens 45, 223-31.-   29. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M. &    Sette, A. (1993) Cell 74, 929-37.-   30. Parker, K. C., Bednarek, M. A. & Coligan, J. E. (1994) J.    Immunol. 152, 163-75.-   31. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A. &    Chesnut, R. W. (1991) J. Exp. Med. 173, 1007-15.-   32. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina,    R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., Ruppert, J. &    et al. (1994) J. Immunol. 153, 5586-92.-   33. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M.    & Melief, C. J. (1996) J. Immunol. 156, 3308-14.-   34. Sommerfeld, H. J., Meeker, A. K., Piatyszek, M. A., Bova, G. S.,    Shay, J. W. & 20 Coffey, D. S. (1996) Cancer Research 56, 218-22.-   35. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K.,    Michel, H., Sevilir, N., Cox, A. L., Appella, E. &    Engelhard, V. H. (1992) Science 255, 1261-3.-   36. Quaranta, V., Zanetti, M. & Reisfeld, R. A. (1982) J. Exp. Med.    156, 1551-6.-   37. Zanetti, M., Filaci, G., Lee, R. H., del Guercio, P., Rossi, F.,    Bacchetta, R., Stevenson, F., Barnaba, V. & Billetta, R. (1993)    EMBO J. 12, 4375-4384.-   38. Hiyama, K., Ffirai, Y., Kyoizumi, S., Akiyama, M., Hiyama, E.,    Piatyszek, M. A., Shay, J. W., Ishioka, S. & Yamakido, M. (1995) J.    Immunol. 155, 3711-5.-   39. Pascolo, S., Bervas, N., Ure, J. M., Smith, A. G.,    Lemonnier, F. A. & Perarnau, B. (1997) J Exp Med 185, 2043-51.-   40. Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D.,    Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., Bunn, P. &    et al. (1985) 1 Exp. Med. 161, 1135-51.-   41. Momburg, F., Degener, T., Bacchus, E., Moldenhauer, G.,    Heammerling, G. J. & Meoller, P. (1986) Int. J. Cancer 37, 179-84.-   42. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W.,    Mule, J. J., Rosenberg, S. A. & Bennink, J. R. (1993) J. Exp. Med.    177, 265-272.-   43. Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L.,    Keating, P. J., Stern, P. L., Meijer, C. J. &    Walboomers, J. M. (1994) J. Exp. Med. 179, 335-340.-   44. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P.,    Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E.,    Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R.,    Kawakami, Y., Seipp, C. A., Einhorn, J. H. & White, D. E. (1998)    Nature Medicine 4, 321-327.-   45. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, M., Grabbe, S.,    Dummer, R., Burg, G. & Schadendorf, D. (1998) Nature Medicine 4,    328-332.-   46. Thomson, S. A., Sherritt, M. A., Medveczky, J., Elliott, S. L.,    Moss, D. J., Fernando, G. J., Brown, L. E. & Suhrbier, A. (1998) J.    Immunol. 160, 1717-23.-   47. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J. &    Eisen, H. N. (1996) Immunity 4, 565-71.-   48. Morgan, D. J., Krcuwd, H. T., Fleck, S., Levitsky, H. I.,    Pardoll, D. M. & Sherman, L. A. (1998) J. Immunol. 160, 643-51.-   49. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R.,    Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B.,    Rosenberg, S. A. & Restifo, N. P. (1999) Proc. Natl. Acad. Sci. USA    96, 2982-7.-   50. Hu, J., Kindsvogel, W., Busby, S., Bailey, M. C., Shi, Y. Y. &    Greenberg, P. D. (1993) J. Exp. Med. 177, 1681-90,-   51. Uyttenhove, C., Godfraind, C., Lethae, B., Amar-Costesec, A.,    Renauld, J. C., Gajewski, T. F., Duffour, M. T., Warnier, G.,    Boon, T. & Van den Eynde, B. J. (1997) Int. J. Cancer 70, 349-56.-   52. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and    Rammensee, H. G. (1991) Nature 351, 290-6.-   53. Fernandez-Vina, M. A., Falco, M., Sun, Y., and Stastny, P.    (1992), Human Immunology 33, 163-73.-   54. Firat, H., Garcia-Pons, F., tourdot, S., Pascolo, S., Scardino,    A., Garcia, Z., Michel, M.-L., Jack, R., Jung, G., Kostmatopoulos,    K., Mateo, L., Suhbrbier, A., Lemonnier, F., and    Langlade-Demoyen, P. (1999) Eur. J. Immunol. 29, 3112-3121.-   55. Krausa, P., Brywka, M., 3rd, Savage, D., Hui, K. M., Bunce, M.,    Ngai, J. L., Teo, D. L., Ong, Y. W., Barouch, D., Allsop, C. E., and    et al. (1995). Genetic polymorphism within HLA-A*02: significant    allelic variation revealed in different populations. Tissue Antigens    45, 223-31.-   56. Lee, T. D. (1990) In The HLA System, J. Lee, ed. (New York:    Springer-Verlag), pp. 141-178.-   57. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L.,    Andrews, W. H., Lingner, J., Harley, C. B., and Cech, T. R. (1997)    [see comments]. Science 277, 955-9.-   58. Parker, K. C., Bednarek, M. A., and Coligan, J. E. (1994)    Journal of Immunology 152, 163-75.-   59. Rotzschke, O., Falk, K., Deres, K., Schild, H., Norda, M.,    Metzger, J., Jung, G., and Rammensee, H.-G. (1990) Nature 348,    252-254.-   60. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M.,    and Sette, A. (1993) Cell 74, 929-37.-   61. Schumacher, T. N., De Bruijn, M. L., Vernie, L. N., Kast, W. M.,    Melief, C. J., Neefjes, J. J., and Ploegh, H. L. (1991) Nature 350,    703-6.

1. An isolated peptide consisting of the amino acid sequence of SEQ IDNO:1 or SEQ ID NO:2.
 2. The isolated peptide of claim 1 consisting ofthe amino acid sequence of SEQ ID NO:1.
 3. The isolated peptide of claim1 consisting of the amino acid sequence of SEQ ID NO:2.
 4. A compositioncomprising the isolated peptide of claim 1 and a physiologicallyacceptable carrier.
 5. The composition of claim 4, wherein said carrieris a mammalian cell.